Lilly's Retatrutide Posts Up to 30% Weight Loss in Obesity Trial and 20.8% in Diabetes Study as Novo Touts Wegovy Pill Switch Data

SentiSense · Published Sep 29, 2026, 6:00 PM ET · Updated Sep 30, 2026, 12:03 PM ET

Eli Lilly's triple agonist retatrutide produced average weight loss of 25% at 80 weeks and 30% at 104 weeks on the top dose in a late-stage obesity tr...